阜阳中医白斑的治疗(阜阳座疮去哪家医院) (今日更新中)

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

YANGON, Nov. 10 (Xinhua) -- Myanmar surgeons have successfully separated the fifth conjoined twin baby girls, official media reported Thursday.The surgical operation by Dr. Htoo Han and his assistants was performed on the two-year-and-one-month-old conjoined twins named Ma Ingyin Khaing and Ma Ingyin Hlaing in the Children's Hospital in Yangon Wednesday, according to the New Light of Myanmar daily.The separated twins, who are under extensive care in the hospital, are from Kawtin village in Laungton township in southern Tanintharyi region.Myanmar surgeons had carried out four successful similar surgical operations on twins in the past over two decades.The fourth twins, who are also baby girls named So Pyay Lin and So Pyay Win with their chests joined together, were successfully separated in October 2009.

ISLAMABAD, Oct. 15 (Xinhua) -- President Asif Ali Zardari said on Saturday that the government was committed to address the issues of special people including those afflicted with impaired vision and blindness and called for establishing highest standards for their care.In a message on the International White Cane Safety Day, the President asked the people and relevant government agencies to reflect on the problems of visually handicapped people.He asked them to come up with suggestions to achieve high standards in caring for the disabled as these exist in other civilized nations.The White Cane Safety Day was aimed at creating awareness about the problems and requirements of visually handicapped persons and to take practical steps to address these issues. Enditem

BEIJING, Nov. 9 (Xinhua) -- A Chinese Mars orbiter named Yinghuo-1 was successfully launched on Wednesday morning from Russian-leased Baikonur cosmodrome in Kazakhstan, China's authorities said. The orbiter was launched by a Zenit-2 booster rocket at 4:16 a.m. Beijing time Wednesday (2016 GMT Tuesday), hitching a ride on Russia's Phobos-Grunt (Phobos-Soil) craft, an unmanned probe on Phobos, a moon of Mars, said China's State Administration for Sciences, Technology, and Industry for National Defence.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.

来源：资阳报